Trial reportJournal of cosmetic dermatology2025
Translational Application of Recombinant Humanized Type III Collagen in Facial Rejuvenation: A Randomized Controlled Trial.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Translational Application of Recombinant Humanized Type III Collagen in Facial Rejuvenation: A Randomized Controlled Trial.Journal of cosmetic dermatology · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSkin aging is a common aesthetic concern that drives the demand for new therapeutic strategies. Lyophilized injectable recombinant humanized type III collagen (rhCol III) is an emerging biomaterial with promising regenerative potential; however, clinical data on its efficacy is limited. This study aimed to evaluate the safety and effectiveness of rhCol III in improving the signs of skin aging.
methodsA total of 55 participants were enrolled in the study. Those in the treatment group received "water-light" intradermal injections of the study product alongside their routine skincare regimen. The control group continued with the routine skincare regimen alone. Clinical efficacy was assessed after treatment using VISIA imaging, evaluations by professional dermatologists, and self-assessments by the participants.
resultsOf the 52 participants who completed the follow-up (39 in the treatment group, 13 in the control group), scores on the Global Aesthetic Improvement Scale (GAIS) improved significantly in the treatment group at day 90 ± 7 (from 3.17 ± 0.39 to 2.97 ± 0.58), with no notable change in the control group. CMH chi-square analysis revealed a significant difference in response rates (71.8%; 95% CI: 54.2%-89.4%). VISIA analysis showed significant improvements in spots, wrinkles, texture, and porphyrins (corrected p < 0.00625). Generalized estimating equation (GEE) modeling supported a time-dependent cumulative effect. The treatment was well tolerated, with stable visual analogue scale (VAS) scores and no serious adverse events.
conclusionThis preliminary study indicates that lyophilized rhCol III can significantly improve the appearance of the skin and is safe to use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.